Journal Browser

► Journal Browser

Special Issue "Challenges and Innovative Solutions in Nasal Drug Delivery: From Formulation Development to Mode of Administration"

Share This Special Issue

Special Issue Editor

Special Issue Information

Dear Colleagues,

Nasal drug administration offers a wide range of therapeutic options including local and systemic drug delivery, brain targeted therapy and mucosal vaccination. However, its potential has yet to be fully exploited. Widening the palette of nasally administered drugs requires development of innovative drug formulations enhancing drug availability at the action site. Namely, formulation strategy is the key response to drug solubility, permeation and stability issues as well as mucoadhesive performance. Another key aspect is consideration of efficient drug deposition in specific nasal regions of interest, which is a prerequisite for effective nasal therapy.

This special issue aims to highlight the latest strategies and innovations in development and administration of nasal drug delivery systems. We are pleased to invite you to submit your original research articles or reviews within this subject area. Research topics may include (but not limited to) the following: Development of innovative liquid and powder nasal drug delivery systems; Nanotechnology in nasal drug delivery; In vitro/ex vivo/in vivo characterization methods in nasal formulation development; Nasal deposition studies.

I look forward to receiving your contributions.

Prof. Dr. Anita Hafner
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

innovative nasal drug formulations
local effect
systemic bioavailability
nose-to-brain delivery
mucoadhesion
biocompatiblity
permeability
nasal deposition
nasal delivery device

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Safety in Rats of a Novel Nasal Spray Formulation for the Prevention of Airborne Viral Infections

and

Pharmaceutics 2023, 15(2), 591; https://doi.org/10.3390/pharmaceutics15020591 - 09 Feb 2023

Viewed by 673

Abstract

Hexedra+^® is a nasal spray containing hydroxypropyl methylcellulose, beta-cyclodextrin, and usnic acid. It has been developed with the aim of reducing the risk of transmission of airborne viral infections, with particular reference to influenza and COVID-19. As part of the preclinical development of the product, we carried out a study on thirty male Wistar rats divided into three study groups and treated with Hexedra+, an alternative formulation containing a double concentration of usnic acid (0.015% instead of 0.0075%) or saline solution. Products were administered at the dose of 30 μL into each nostril, three times a day for seven consecutive days by means of a micropipette. By the end of the treatment period, no significant changes were observed in body weight. Histological examination of nasal mucosa and soft organs did not show any significant difference in the three study groups. Serum transaminase level remained in the normal limit in all the animals treated. The serum level of usnic acid was measured in order to assess the absorption of the molecule through the nasal mucosa. By the end of the study period, the usnic acid serum level was negligible in all the animals treated. In conclusion, the safety profile of Hexedra+ appears favorable in the animal model studied. Full article

(This article belongs to the Special Issue Challenges and Innovative Solutions in Nasal Drug Delivery: From Formulation Development to Mode of Administration)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Lipid and Polymeric Nanoparticles: Successful Strategies for Nose-to-Brain Drug Delivery in the Treatment of Depression and Anxiety Disorders

Margarida Alberto

Ana Cláudia Paiva-Santos

Francisco Veiga

and

Patrícia C. Pires

Pharmaceutics 2022, 14(12), 2742; https://doi.org/10.3390/pharmaceutics14122742 - 08 Dec 2022

Cited by 4 | Viewed by 1297

Abstract

Intranasal administration has gained an increasing interest for brain drug delivery since it allows direct transport through neuronal pathways, which can be quite advantageous for central nervous system disorders, such as depression and anxiety. Nanoparticles have been studied as possible alternatives to conventional formulations, with the objective of improving drug bioavailability. The present work aimed to analyze the potential of intranasal nanoparticle administration for the treatment of depression and anxiety, using the analysis of several studies already performed. From the carried-out analysis, it was concluded that the use of nanoparticles allows the drug’s protection from enzymatic degradation, and the modulation of its components allows controlled drug release and enhanced drug permeation. Furthermore, the results of in vivo studies further verified these systems’ potential, with the drug reaching the brain faster and leading to increased bioavailability and, consequently, therapeutic effect. Hence, in general, the intranasal administration of nanoparticles leads to a faster onset of action, with increased and prolonged brain drug concentrations and, consequently, therapeutic effects, presenting high potential as an alternative to the currently available therapies for the treatment of depression and anxiety. Full article

(This article belongs to the Special Issue Challenges and Innovative Solutions in Nasal Drug Delivery: From Formulation Development to Mode of Administration)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Challenges and Innovative Solutions in Nasal Drug Delivery: From Formulation Development to Mode of Administration"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (2 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI